SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

Stock Information for SCYNEXIS Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SCYNEXIS Inc.

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
SCYNEXIS to Participate in Upcoming Investor Conferences
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS Announces One-for-Eight Reverse Stock Split

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.